Most research labs can make cells that produce antibodies. The trick is making those antibodies in sufficient quantity and quality to use throughout clinical trials and for manufacturing scale-up.
Preventing selection bias in the cell line is a critical aspect of cell line development. Selecting clones based on factors such as stability, antibody secretion, or other metrics can result in a ...
Alvotech recently submitted a Citizen Petition to the FDA requesting that the agency refuse to license any ustekinumab biosimilar as interchangeable with STELARA if it is manufactured using a Chinese ...
Production of recombinant monoclonal antibodies (mAbs) for therapeutic use is a multibillion dollar industry. At present, mammalian cell lines are the workhorses of the biotechnology industry, due to ...
For the past 20 years, Abzena has built a strong reputation for producing high-yielding mammalian cell lines for protein targets. By applying the 2G UNic vector technology to their existing CHO ...
With three decades of experience, over 200 client partnerships and several cell-line development platforms, Aragen Bioscience supports its global biopharma clients with end-to-end biologics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results